| Trial | Treatments | Patients | Method |
|---|
| Drexler, 1989 | cilazapril (n=11) vs. placebo (n=10) | patients with chronic heart failure | double blind Sample size: 11/10 Primary endpoint: FU duration: 3 months |
| Dosseger, 1993 | cilazapril titrated up to 2.5 mg/d (n=7) vs. placebo (n=35) | patients with chronic heart failure (NYHA class II to IV) stabilized on digitalis and/or diuretics | double blind Sample size: 7/35 Primary endpoint: exercise tolerance FU duration: 12 weeks |
| Cilazapril-Captopril Multi-centre Group, 1995 | cilazapril 1-2.5 mg once daily (n=221) vs. placebo (n=114) | patients with chronic heart failure (New York Heart Association classes II-IV) | double blind Parallel groups Sample size: 221/114 Primary endpoint: exercise tolerance FU duration: 12 weeks |
| Cilazapril-Captopril Multi-centre Group (cila vs capt), 1995 | cilazapril 1-2.5 mg once daily (n=221) vs. captopril 25-50mg three times daily (n=108)
| patients with chronic heart failure (New York Heart Association classes II-IV)
| double blind Parallel groups Sample size: 221/108 Primary endpoint: exercise tolerance FU duration: 12 weeks
|
